Skip to content

Enhancing Drug-Resistant TB Patient Care Through Targeted Pharmaceutical Intervention.

Assessment Of pharmaceutical care management In patients with drug-resistant tuberculosis attending treatment at the district TB center and PHC s in Belagavi: A prospective interventional study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087982
Enrollment
150
Registered
2025-05-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention1: Pharmaceutical intervention: Education related to risk factors Intervention2: Pharmaceutical intervention: Education related to importance of Medication adherence Intervention3: Pharma

Sponsors

Mr. Vishwa Rajakumar Byakod
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects aged 18 or above of either Gender Subjects with comorbid conditions. Patients suffering with DR-TB Patients suffering from Pulmonary and Extra-pulmonary

Exclusion criteria

Exclusion criteria: Patients with less than 18 years of age Patients who refuse to participate in the study.

Design outcomes

Primary

MeasureTime frame
Assessment of possible risk factors for DR-TB patients Identification and Mitigation of DRPs Improved HRQOL and Medication Adherence Reduced DR-TB Progression Overall Enhanced Pharmaceutical CareTimepoint: 2 years

Secondary

MeasureTime frame
Improved Knowledge, Attitudes, and Practices (KAP) Regarding ADR Reporting Development and Utilization of Effective Educational Tools Effective Use of Nikshay and ABHA Portals Overall Impact on DR-TB ManagementTimepoint: 2 years

Countries

India

Contacts

Public ContactDr M S Ganachari

KLE College of Pharmacy, Belagavi.

msganachari@gmail.com9448634457

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026